DNMT1 and hematologic disorder: DNMT inhibitors, such as 5-azacitidine (5-AZA) and decitabine (DAC), are approved and have been used successfully for treating hematological malignancies [8], showing promising in vitro and in vivo results in solid neoplasms [9].